Recent advances in the chemotherapy of lymphatic filariasis.
Lymphatic filariasis is the most widespread of human filarial infections, a group of vector-borne infestations. After the discovery of diethylcarbamazine (DEC), little advance was made in the development of new chemotherapeutic agents for the treatment of lymphatic filariasis until 1985. Since then, several new initiatives have occurred as the result of a global effort by the World Bank/UNDP/WHO Special Programme on Tropical Diseases and the Onchocerciasis Control Programme. Some of these global research initiatives are reviewed in this paper. Recent observations throw a new light on the rational use of DEC including its deployment as a medicated salt. Ivermectin, an established drug for the treatment of river-blindness is examined for its potential use in the treatment of lymphatic filariasis. Experimental results from two novel compounds out of several being developed by the WHO/OCP Macrofil project are considered in respect to their potential macrofilaricidal activity, particularly in relation to lymphatic filarial infections.
Navaratnam
V
V
Center for Drug Research, Universiti Sains Malaysia, Penang.
D001562:Benzimidazoles / Q000627:therapeutic use; D052160:Benzothiazoles; D004049:Diethylcarbamazine / Q000627:therapeutic use; D004605:Elephantiasis, Filarial / Q000188:drug therapy*; D005369:Filaricides / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D007559:Ivermectin / Q000627:therapeutic use; D013827:Thiabendazole / Q000627:therapeutic use; D013844:Thiazoles / Q000627:therapeutic use
D001562:Benzimidazoles; D052160:Benzothiazoles; D005369:Filaricides; D013844:Thiazoles; D007559:Ivermectin; C005465:benzothiazole; D013827:Thiabendazole; D004049:Diethylcarbamazine